News & Updates

A TAVI*-first strategy is noninferior to performing PCI** first when it comes to clinical outcomes at 1 year in patients with severe aortic stenosis and concomitant coronary artery disease (CAD), according to the TAVI PCI trial presented at ESC 2026.

Low-voltage zone ablation, when performed in addition to pulmonary vein isolation, helps improve rhythm outcomes and health-related quality of life in patients with persistent atrial fibrillation (AF) and significant low-voltage zones, according to the IDEAL-AF trial.

Women with pre-eclampsia face a heightened risk of subsequent kidney disease within the first postpartum year when compared with those whose pregnancies are complicated by gestational hypertension, as shown in a retrospective study.

Relaxed prescription requirements for add-on sodium-glucose cotransporter 2 inhibitors (SGLT2i) now allow earlier use of these cardiorenal-protective therapies in eligible patients as the second antidiabetic medication after metformin. Dr Paul Lee and Dr David Lui, Specialists in Endocrinology, Diabetes & Metabolism in Hong Kong, discussed how changes in SGLT2i prescription requirements may benefit patients with type 2 diabetes (T2D) who have chronic kidney disease (CKD) or established cardiovascular disease (CVD), and the role of SGLT2i (eg, empagliflozin) in cardiovascular-kidney-metabolic (CKM) syndrome management.

Advanced cardiovascular-kidney-metabolic (CKM) syndrome (stages 3 and 4) is associated with higher risks of all-cause and cardiovascular (CV) mortality at 20 years, according to a prospective study in Hong Kong.

Consumption of fresh or pasteurized sauerkraut both delivers a modest impact on blood pressure (BP) in healthy individuals, suggesting that pasteurization does not remove the physiological impact of this fermented food, reveals a study.

Treatment with aficamten significantly improves patient-reported health status and exercise capacity in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM), according to the ACACIA-HCM trial presented at ESC 2026.

Treatment with tirzepatide does not appear to be associated with atrial fibrillation or atrial arrhythmia in individuals with overweight or obesity, according to a meta-analysis.

Researchers from the Chinese University of Hong Kong (CUHK) and the Chinese Academy of Sciences (CAS)–CUHK Joint Laboratory for Cardiovascular Sciences have discovered that de novo coronary collaterals formed after myocardial infarction (MI) arise primarily through arterialization of capillaries, with only a modest contribution from pre-existing arteries, challenging the long-held belief that new arteries arise from pre-existing arteries.